Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03444844 · ClinicalTrials.gov registry record · Phase 1
Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer
A Phase 1 study of Prostate Cancer and Prostate Cancer Recurrent, sponsored by Five Eleven Pharma.
- Active
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT03444844 is a Phase 1 study of Prostate Cancer and Prostate Cancer Recurrent that is active but no longer recruiting, run by Five Eleven Pharma. The registered enrollment target is 60 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03444844, a Phase 1 study of Prostate Cancer and Prostate Cancer Recurrent, is active but no longer recruiting, sponsored by Five Eleven Pharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Initial performance of Ga-68-P16-093 in prostate cancer patients including dosimetry and preliminary efficacy evaluation in BCR patients, and correlation of Ga-68-P16-093 uptake with tissue histopathology in intermediate to high risk primary prostate cancer patients.
Conditions Studied
Interventions
- DRUG Ga-68 P16-093 PET/CT scan
Study Locations (1)
Indiana
- Goodman Hall, Indiana Institute for Biomedical Imaging Sciences, Indiana University School of Medicine - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2018-05-10 |
| Est. Completion | 2022-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03444844
The ClinicalTrials.gov registry entry for NCT03444844 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Five Eleven Pharma, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Ga-68 P16-093 PET/CT scan is the first listed.
NCT03444844 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT03444844 about?
NCT03444844 is a clinical study titled "Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer". Initial performance of Ga-68-P16-093 in prostate cancer patients including dosimetry and preliminary efficacy evaluation in BCR patients, and correlation of Ga-68-P16-093 uptake with tissue histopathology in intermediate to high risk primary prostate cancer patients.
What is the current status of trial NCT03444844?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2018-05-10. Estimated completion is 2022-07.
What conditions does trial NCT03444844 study?
This clinical trial studies the following conditions: Prostate Cancer, Prostate Cancer Recurrent.
What interventions are being tested in trial NCT03444844?
The interventions under investigation include: Ga-68 P16-093 PET/CT scan (DRUG).
Who is sponsoring clinical trial NCT03444844?
This trial is sponsored by Five Eleven Pharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03444844 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.